Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in greater weight loss compared with placebo in people who have overweight or ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop ...

I think it’s going to be powerful.” Bergenstal said trials exploring the combination of a GLP-1, insulin icodec and CGM should be conducted in the future. References: ...

Initial combination therapy of sitagliptin, a once-daily, orally active, potent selective and reversible DPP-4 inhibitor and metformin (Janumet), demonstrates a substantial, additive and sustained ...

Now, this very exciting preclinical data combining next generation insulin sensitizer 0602K with a state-of-the-art GLP-1 /GIP receptor agonist, tirzepatide, further supports the enormous potential.